A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer

Completed · Phase 1

Conditions studied: Prostate Cancer

In brief

The primary purpose of this study is to evaluate the ability of oral triamcinalone given twice a day to patients with androgen independent prostate cancer to produce a sustained biochemical response. Secondary goals are to describe the safety and tolerability at this dose and schedule, to determine the time to sustained biochemical response, to determine the duration of biochemical response, to determine the time to disease progression.

Key facts

Study ID

NCT00186108

Run by

Stanford University

People needed

23

Starts

2002-10-01

Expected to finish

2005-09-01

Last updated by the study team

2007-07-25

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age and older
• Histologically documented adenocarcinoma of prostate
• Currently receiving LHRH agonists with castrate levels of testosterone or who have had an orchiectomy
• Must have had a rise in PSA despite anti androgen withdrawal
• Exhibit 2 consecutive rise in PSA after the last hormonal manipulation
• Minimum PSA of greater than 5 KPS greater than 80%
• Normal cortisol level at entry
• Life expectancy greater than 6 months
• Provide written consent pursuant to regulatory requirements prior to initiation of study procedure

You may not qualify if…

• Younger than 18 years
• Patients without prostate cancer

Where it is running

• Stanford University Cancer Center — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.